Dabigatran Impurities

veeprho banner
Parent Drug Name Name of Impurity Catalogue No.
Dabigatran Dabigatran Amide Impurity VL1760004View CAS 1580491-16-2
Dabigatran Dabigatran Etexilate VE008337View CAS 211915-06-9
Dabigatran Dabigatran Etexilate Mesylate Impurity A VE006258View
Dabigatran Dabigatran Etexilate Mesylate Impurity B VE006259View
Dabigatran Dabigatran Etexilate Mesylate Impurity C VE006260View
Dabigatran Dabigatran Etexilate Mesylate Impurity D VE006268View
Dabigatran Dabigatran Etexilate Mesylate Impurity E VE006269View
Dabigatran Dabigatran Impurity 2 VL1760002View CAS 42288-26-6
Dabigatran Dabigatran Impurity 6 VL1760003View CAS 211914-51-1
Dabigatran Dabigatran Impurity P VL1760001View CAS 1408238-37-8
Dabigatran Dabigatran Nitrosamine Impurity VE0010606View
Dabigatran Dabigatran impurity 8 VL1760005View CAS 872728-81-9

Request a quote

1408238-37-8: Dabigatran Impurity P

1408238-37-8: Dabigatran Impurity P
Catalogue No.

VL1760001
CAS No.

1408238-37-8
Molecular Formula

C₃₂H₃₆N₆O₆
Molecular Weight

600.66
Parent drug

Dabigatran
IUPAC Name

3-(2-(((4-(((Hexyloxy)carbonyl)carbamoyl)phenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoic Acid
Synonyms

Dabigatran Etexilate Mesylate Impurity A; Dabigatran Etexilate Di-Amide Acid
References

Pantovi, Jasmina, et al. “Development of Liquid Chromatographic Method for the Analysis of Dabigatran Etexilate Mesilate and Its Ten Impurities Supported by Quality-By-Design Methodology.” Journal of Pharmaceutical and Biomedical Analysis, vol. 111, July 2015, pp. 7–13, https://doi.org/10.1016/j.jpba.2015.03.009.Legrand, Matthieu. “The Use of Dabigatran in Elderly Patients.” Archives of Internal Medicine, vol. 171, no. 14, July 2011, p. 1285, https://doi.org/10.1001/archinternmed.2011.314.
Status

In-stock
ListName

Dabigatran Impurity P
Exclusively Supplied by Veeprho

Exclusively Supplied by Veeprho

"*" indicates required fields

Hidden
Products quotation
Name
Url